Concepts of Tumor Lectinology

References

• Glycoprotein Analysis in Biomedicine. Meth Mol Biol, E F Hounsell. Humana Press, Totowa, NJ 1993; Vol 14
   Google Scholar
• Dwek R A, Edge C J, Harvey D J, et al. Analysis of glycoprotein-as-sociated oligosaccharides. Annu Rev Biochem 1993; 62: 65–100
   PubMed Web of Science ®Google Scholar
• Glycoproteins, J Monireuil, J FG Vliegenthart, H Schachler. Elsevier, Amsterdam 1995
   Google Scholar
• Kobata A. Structures and functions of the sugar chains of glycoproteins. Eur J Biochem 1992; 209: 483–501
   PubMedGoogle Scholar
• Lis H, Sharon N. Protein glycosylation. Structural and functional aspects. Eur J Biochem 1993; 218: 1–27
   PubMedGoogle Scholar
• Laine R A. The information-storing potential of the sugar code. Glycosciences: Status and Perspectives, H J Gabius, S Gabius. Chapman & Hall, London 1997; 1–14
   Google Scholar
• Varki A. Biological roles of oligosaccharides: All of the theories are correct Glycobiology 1993; 3: 97–130
   Google Scholar
• Baenziger J U. Protein-specific glycosyltransferases: How and why they do it. FASEB J 1994; 8: 1019–1025
   PubMed Web of Science ®Google Scholar
• Spicer S S, Schulte B A. Diversity of cell glycoconjugates shown histochemically: A perspective. J Histochem Cytochem 1992; 40: 1–38
   PubMed Web of Science ®Google Scholar
• Lectins and Glycobiology, H J Gabius, S Gabius. Springer, Heidelberg 1993
   Google Scholar
• Vijayakumar T, Remani P, Ankathil R, et al. Plant lectins in immunology, cytology and hematology: A bibliography and projects for development Hematol Rev 1994; 8: 151–168
   Google Scholar
• Danguy A. Perspectives in modern glycohistochemistry. Eur J Histochem 1995; 39: 5–14
   PubMed Web of Science ®Google Scholar
• Alhadeff J A. Malignant cell glycoproteins and glycolipids. CRC Crit Rev Oncol/Hematol 1989; 9: 37–107
   PubMed Web of Science ®Google Scholar
• Hakomori S. Aberrant glycosylation in tumors and tumor-asso-cialed carbohydrate antigens. Adv Cancer Res 1989; 52: 257–331
   PubMed Web of Science ®Google Scholar
• Walker R A. The use of lectins in histopathology. Pathol Res Pract 1989; 185: 826–835
   PubMed Web of Science ®Google Scholar
• Sell S. Cancer-associated carbohydrates identified by monoclonal antibodies. Hum Pathol 1990; 21: 1003–1019
   PubMed Web of Science ®Google Scholar
• Lectins and Cancer, H J Gabius, S Gabius. Springer, Heidelberg 1991
   Google Scholar
• Muramatsu T. Carbohydrate signals in metastasis and prognosis of human carcinomas. Glycobiology 1993; 3: 291–296
   PubMedGoogle Scholar
• Mody R, Joshi S S, Chaney W. The use of lectins as diagnostic and therapeutic tool for cancer. J Pharmacol Toxicol Meth 1995; 33: 1–10
   PubMed Web of Science ®Google Scholar
• Barondes S H. Bifunctional properties of lectins: lectins redefined. Trends Biochem Sci 1988; 13: 480–482
   PubMed Web of Science ®Google Scholar
• Gabius H J. Vertebrate lectins and their possible roles in fertilization, development and tumor biology. In Vivo 1987; 1: 75–84
   PubMedGoogle Scholar
• Sharon N, Lis H. Lectins as cell recognition molecules. Science 1989; 246: 227–234
   PubMed Web of Science ®Google Scholar
• Gabius H J. Detection and functions of mammalian lectins-With emphasis on membrane lectins. Biochim Biophys Acta 1991; 1071: 1–18
   PubMed Web of Science ®Google Scholar
• Powell L D, Varki A. I-type lectins. J Biol Chem 1995; 270: 14243–14246
   PubMed Web of Science ®Google Scholar
• Zanetta J P. Lectins and carbohydrates in animal cell adhesion and control of proliferation. Glycosciences: Status and Perspectives, H J Gabius, S Gabius. Chapman & Hall, London 1997; 439–458
   Google Scholar
• Gabius H J. Endogenous lectins in tumors and the immune system. Cancer Invest 1987; 5: 39–46
   PubMed Web of Science ®Google Scholar
• Krantz M J, Holtzman N A, Stowell C P, et al. Attachment of thio-glycosides to proteins: Enhancement of liver membrane binding. Biochemistry 1976; 15: 3963–3968
   PubMed Web of Science ®Google Scholar
• Stowell C P, Lee Y C. Neoglycoproteins: The preparation and application of synthetic glycoproteins. Adv Carbohydr Chem Biochem 1981; 37: 225–281
   Google Scholar
• Neoglycoconjugates. Preparation and Applications, Y C Lee, R T Lee. Academic Press, San Diego 1994
   Google Scholar
• Danguy A, Kayser K, Bovin N V, et al. The relevance of neoglyco-conjugates for histology and pathology. Trends Glycosci Gly-cotechnol 1995; 7: 261–275
   Web of Science ®Google Scholar
• Bovin N V, Gabius H J. Polymer-immobilized carbohydrate ligands: Versatile chemical tools for biochemistry and medical sciences. Chem Soc Rev 1995; 24: 413–421
   Web of Science ®Google Scholar
• Gabius H J, Gabius S, Zemlyanukhina T V, et al. Reverse lectin histochemistry: Design and application of glycoligands for detection of cell and tissue lectins. Histol Histopathol 1993; 8: 369–383
   PubMed Web of Science ®Google Scholar
• Monsigny M, Roche A C, Midoux P, . Endogenous lectins of myeloid and tumor cells: Characterization and biological implications. Lectins and Glycoconjugates in Oncology, H J Gabius, G A Nagel, et al. Springer, Heidelberg 1988; 25–47
   Google Scholar
• Gabius H J, Gabius S. Chemical and biochemical strategies for the preparation of glycohistochemical probes and their application in lectinology. Adv Lectin Res 1992; 5: 123–157
   Google Scholar
• Midoux P, Roche A C, Monsigny M. Estimation of the degradation of endocytosed material by flow cytofluorometry using two neoglycoproteins containing different numbers of fluorescein molecules. Biol Cell 1986; 58: 221–226
   PubMed Web of Science ®Google Scholar
• Gabius H J, AndrÉ S, Danguy A, et al. Detection and quantification of carbohydrate-binding sites on cell surfaces and in tissue sections by neoglycoproteins. Meth Enzymol 1994; 242: 37–46
   PubMed Web of Science ®Google Scholar
• Gabius H J. Tumor lectinology: At the intersection of carbohydrate chemistry, biochemistry, cell biology and oncology. Angew Chem Int Ed Eng 1988; 27: 1267–1276
   Web of Science ®Google Scholar
• Monsigny M, Roche A C, Midoux P, et al. Glycoconjugates as carriers for specific drug delivery of therapeutic drugs and genes. Adv Drug Deliv Rev 1994; 14: 1–24
   Web of Science ®Google Scholar
• Molema G, Meijer D KF. Targeting of drugs to various blood cell types using neoglycoproteins, antibodies and other carrier proteins. Adv Drug Deliv Rev 1994; 14: 25–50
   Web of Science ®Google Scholar
• Seymour L W. Soluble polymers for lectin-mediated drug targeting. Adv Drug Deliv Rev 1994; 14: 89–111
   Web of Science ®Google Scholar
• Frese J, Wu C H, Wu G Y. Targeting of genes to the liver with glycoprotein carriers. Adv Drug Deliv Rev 1994; 14: 137–152
   Web of Science ®Google Scholar
• Wadhwa M S, Rice K G. Receptor-mediated glycotargeting. J Drug Targ 1995; 3: 111–127
   PubMed Web of Science ®Google Scholar
• Kayser K, Bovin N V, Zemlyanukhina T V, et al. Cell type-dependent alterations of binding of synthetic blood group antigen-related oligosaccharides in lung cancer. Glycoconjugate J 1994; 11: 339–344
   PubMed Web of Science ®Google Scholar
• Vellupillai P, Ham D A. Oligosaccharide-specific induction of in-terleukin-10 production by B220+ cells from schistosome-infected mice: A mechanism for regulation of CD4+ T-cell subsets. Proc Natl Acad Sci USA 1994; 91: 18–22
   PubMed Web of Science ®Google Scholar
• Hiraishi K, Suzuki K, Hakomori S, et al. Le+ antigen expression is correlated with apoptosis (programmed cell death). Glycobiology 1993; 3: 381–390
   PubMed Web of Science ®Google Scholar
• Lotan R, Raz A. Endogenous lectins as mediators of tumor cell adhesion. J Cell Biochem 1988; 37: 107–117
   PubMed Web of Science ®Google Scholar
• Gabius S, Schirrmacher V, Franz H, et al. Analysis of cell surface sugar receptor expression by neoglycoenzyme binding and adhesion to plastic-immobilized neoglycoproteins for related weakly and strongly metastatic cell lines of murine tumor model systems. Int J Cancer 1990; 46: 500–507
   PubMed Web of Science ®Google Scholar
• Gabius S, Wawotzny R, Wilholm S, et al. Adhesion of human lymphoid cell lines to immobilized carbohydrates and to bone marrow stromal cell layers by surface sugar receptors. Int J Cancer 1993; 54: 1017–1021
   PubMed Web of Science ®Google Scholar
• Seshi B. Discovery of novel hematopoietic cell adhesion molecules from human bone marrow stromal cell membrane protein extracts by a new cell-blotting technique. Blood 1994; 83: 2399–2409
   PubMed Web of Science ®Google Scholar
• Inohara H, Raz A. Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Res 1995; 55: 3267–3271
   PubMed Web of Science ®Google Scholar
• White T K, Zhu Q, Tanzer M L. Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell spreading. J Biol Chem 1995; 270: 15926–15929
   PubMed Web of Science ®Google Scholar
• Nangia-Makker P, Thompson E, Hogan C, et al. Induction of tumorigenicity by galectin-3 in a non-tumorigenic human breast carcinoma cell line. Int J Oncol 1995; 7: 1079–1087
   PubMed Web of Science ®Google Scholar
• Oguchi H, Toyokuni T, Dean B, et al. Effect of lactose derivatives on metastatic potential of B16 melanoma cells. Cancer Commun 1990; 2: 311–316
   PubMed Web of Science ®Google Scholar
• Woynarowska B, Skrincosky D M, Haag A, et al. Inhibition of lectin-mediated ovarian tumor cell adhesion by sugar analogs. J Biol Chem 1994; 269: 22797–22803
   PubMed Web of Science ®Google Scholar
• Pienta K J, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 1995; 87: 348–353
   PubMed Web of Science ®Google Scholar
• Corral I, Kerbel R S, Dennis J W. Tumor cell surface β1–4-linked galactose binds to lectin(s) on microvascular endothelial cells and contributes to organ colonization. J Cell Biol 1990; 111: 773–781
   PubMed Web of Science ®Google Scholar
• Lotan R, Belloni P N, Tressler R J, et al. Expression of galectins on microvessel endothelial cells and their involvement in tumor cell adhesion. Glycoconjugate J 1994; 11: 462–468
   PubMed Web of Science ®Google Scholar
• Welply J K, Keene J L, Schmuke J I, et al. Selectins as potential targets of therapeutic intervention in inflammatory disease. Biochim Biophys Acta 1994; 1197: 215–226
   PubMed Web of Science ®Google Scholar
• Lasky C A. Selectin-carbohydrate interactions and the initiation of the inflammatory response. Annu RevBiochem 1995; 64: 113–139
   PubMed Web of Science ®Google Scholar
• Plcndl J, Sinowatz F, Auerbach R, et al. Quantitative differences in neoglycoprotein binding for vascular endothelial cells from porcine brain, ovary and testis in vitro. Microvasc Res 1995; 50: 199–214
   PubMed Web of Science ®Google Scholar
• Dintzis R Z, Okajima M, Middleton M H, et al. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol 1989; 143: 1239–1244
   PubMed Web of Science ®Google Scholar
• Livingston P O. Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens. Curr Opinion Immunol 1992; 4: 624–629
   PubMed Web of Science ®Google Scholar
• Maclean G D, Reddish M A, Bowen-Yacyshyn M B, et al. Active specific immunotherapy against adenocarcinomas. Cancer Invest 1994; 12: 46–56
   PubMed Web of Science ®Google Scholar
• Gabius H J, Bardosi A. Neoglycoproteins as tools in glycohisto-chemistry. Progr Histochem Cytochem 1991; 22: 1–66
   PubMed Web of Science ®Google Scholar
• Raz A, Meromsky L, Zvibel I, et al. Transformation-related changes in the expression of endogenous cell lectins. Int J Cancer 1987; 39: 353–360
   PubMed Web of Science ®Google Scholar
• Gabius S, Hellmann K P, Ciesiolka T, et al. Lineage- and differentiation-dependent alterations in the expression of receptors for glycoconjugates (lectins) in different human hematopoietic cell lines and low grade lymphomas. Blut 1989; 59: 165–170
   PubMedGoogle Scholar
• Lotan R, Lotan D, Carralero D M. Modulation of galactoside-bind-ing lectins in tumor cells by differentiation-inducing agents. Cancer Lett 1989; 48: 115–122
   PubMed Web of Science ®Google Scholar
• Gabius S, Yamazaki N, Hanewacker W, et al. Regulation of distribution, amount and ligand affinity of sugar receptors in human colon carcinoma cells by treatment with sodium butyrate, retinoic acid and phorbol ester. Anticancer Res 1990; 10: 1005–1012
   PubMed Web of Science ®Google Scholar
• Gabius H J, Gabius S, Frilsche M, et al. Transformation-associated decrease in cell surface binding of neoglycoenzymes in a temperature-sensitive, virally transformed mouse model. Naturwissen-schaficn 1991; 78: 230–232
   PubMed Web of Science ®Google Scholar
• Vidal-Vanaclocha F, Barbera-Guillem E, Weiss L, et al. Quantitation of endogenous lectin expression in 3LL tumors, growing subcutaneously and in the kidneys of mice. Int J Cancer 1990; 46: 908–912
   PubMed Web of Science ®Google Scholar
• Gabius H J, Brehler R, Schauer A, et al. Localization of endogenous lectins innormal human breast, benign breast lesions and mammary carcinomas. Virch Arch [Cell Pathol] 1986; 52: 107–115
   Web of Science ®Google Scholar
• Irimura T, Matsushita Y, Sutton R C, et al. Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 1991; 51: 387–393
   PubMed Web of Science ®Google Scholar
• Lotan R, Ito H, Yasui W, et al. Expression of a 31-kDa lactose-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 1994; 56: 474–480
   PubMed Web of Science ®Google Scholar
• Chiarotti L, Berlingieri M T, Battaglia C, et al. Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int J Cancer 1995; 64: 171–175
   PubMed Web of Science ®Google Scholar
• Schoeppner H L, Raz A, Ho S B, et al. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 1995; 75: 2818–2826
   PubMed Web of Science ®Google Scholar
• Xu X C, El-Naggar A K, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Am J Pathol 1995; 147: 815–822
   PubMed Web of Science ®Google Scholar
• Ohannesian D W, Lotan D, Lotan R. Concomitant increases of galectin-1 and its glycoprotein ligands (carcinoembryonic antigen, Lamp-1, and Lamp-2) in cultured human colon carcinoma cells by sodium butyrate. Cancer Res 1994; 54: 5992–6000
   PubMed Web of Science ®Google Scholar
• Ohannesian D W, Lotan D, Thomas P, et al. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 1995; 55: 2191–2199
   PubMed Web of Science ®Google Scholar
• Gabius H J, Kohnke-Godt B, Leichsenring M, et al. Heparin-bind-ing lectin of human placenta as a tool for histochemical ligand localization and ligand isolation. J Histochem Cytochem 1991; 39: 1249–1256
   PubMed Web of Science ®Google Scholar
• Slcat D E, Chen T L, Raska K, et al. Increased levels of glycoproteins containing mannose-6-phosphate in human breast carcinomas. Cancer Res 1995; 55: 3424–3430
   PubMed Web of Science ®Google Scholar
• Dube V E. The structural relationship of blood group-related oligosaccharides in human carcinomas to biological function: A perspective. Cancer Metast Rev 1987; 6: 541–557
   PubMed Web of Science ®Google Scholar
• Hakomori S. Possible functions of tumor-associated carbohydrate antigens. Curr Opin Immunol 1991; 3: 646–653
   PubMed Web of Science ®Google Scholar
• King M J. Blood group antigens on human erythrocytes: distribution, structure and possible functions. Biochim Biophys Acta 1994; 1197: 15–44
   PubMed Web of Science ®Google Scholar
• Orntoft T F, Bech E. Circulating blood group-related carbohydrate antigens as tumor markers. Glycoconjugate J 1995; 12: 200–205
   PubMed Web of Science ®Google Scholar
• Kayser K, Bovin N V, Korchagina E Y, et al. Correlation of expression of binding sites for synthetic blood group A-, B-, and H-trisac-charides and for sarcolectin with survival of patients with bronchial carcinoma. Eur J Cancer 1994; 30A: 653–657
   PubMed Web of Science ®Google Scholar
• Kayser K, Bovin N V, Zeng F Y, et al. Binding capacities to blood-group antigens A, B, and H, DNA- and MST measurements, and survival in bronchial carcinoma. Radiol Oncol 1994; 28: 282–286
   Google Scholar
• Kayser K, Bubenzer J, Kayser G, et al. Expression of lectin-, interleukin-2-, and histo-blood group-binding sites in prostate cancer and its correlation with integrated optical density and syntactic structure analysis. Analyt Quant Cytol Histol 1995; 17: 135–142
   PubMed Web of Science ®Google Scholar
• Miyake M, Hakomori S. A specific cell surface glycoconjugate controlling cell motility: Evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry 1990; 30: 3328–3334
   Web of Science ®Google Scholar
• Brync M, Thrane P S, Dabelsteen E. Loss of expression of blood group antigen H is associated with cellular invasion and spread of oral squamous cell carcinomas. Cancer 1991; 67: 613–618
   PubMed Web of Science ®Google Scholar
• Miyake M, Taki T, Hitomi S, et al. Correlation of expression of H/Ley/Leb -antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992; 327: 14–18
   PubMed Web of Science ®Google Scholar
• Santos-Benito F F, Fernandez-Mayoralas A, Martin-Lomas M, et al. Inhibition of proliferation of normal and transformed neural cells by blood group-related oligosaccharides. J Exp Med 1992; 176: 915–918
   PubMed Web of Science ®Google Scholar
• Ogawa J, Inoue H, Koida S. Prognostic significance of Lewis x-related antigen exprcsison in stage I non-small cell lung cancer. Eur J Cancer 1995; 31A: 1716
   PubMed Web of Science ®Google Scholar
• Gabius H J. Lectinology meets mythology: Oncological future for the mistletoe lectin?. Trends Glycosci Glycotechnol 1994; 6: 229–238
   Google Scholar
• Gabius H J, Gabius S, Joshi S S, et al. From ill-defined extracts to the immunodulatory lectin: Will there be a reason for oncological application of mistletoe?. Planta Med 1994; 60: 2–7
   PubMed Web of Science ®Google Scholar
• Gabius H J, Walzel H, Joshi S S, et al. The immunomodulatory galactoside-specific lectin from mistletoe: Partial sequence analysis, cell and tissue binding, and impact on intracellular biosignalling of monocytic leukemia cells. Anticancer Res 1992; 12: 669–676
   PubMed Web of Science ®Google Scholar
• Kajikawa T, Nakajima Y, Hirabayashi J, et al. Release of cytotoxin by macrophages on treatment with human placenta lectin. Life Sci 1986; 39: 1177–1181
   PubMed Web of Science ®Google Scholar
• Jeng K CG, Frigeri L G, Liu F T. An endogenous lectin, galectin-3 (εBP/MAC-2), potentiates IL-1 production by human monocytes. Immunol Lett 1994; 42: 113–116
   PubMed Web of Science ®Google Scholar
• Timoshenko A V, Kayser K, Drings P, et al. Modulation of lectin-triggered superoxide release from neutrophils of tumor patients with and without chemotherapy. Anticancer Res 1993; 13: 1789–1792
   PubMed Web of Science ®Google Scholar
• Yamaoka A, Kuwabara I, Frigeri L G, et al. A human lectin, galectin-3 (εBP/MAC-2), stimulates superoxide production by neutrophils. J Immunol 1995; 154: 3479–3487
   PubMed Web of Science ®Google Scholar
• Michiel D F, Oppenheim J J. Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol 1992; 3: 3–15
   PubMedGoogle Scholar
• Neidhart J A. Hematopoietic cytokines. Current use in cancer therapy. Cancer 1993; 72: 3381–3386
   PubMed Web of Science ®Google Scholar
• Ravoet C, De Greve J, Vandewoude K, et al. Tumor stimulating effects of recombinant human interleukin-6. Lancet 1994; 344: 1576–1577
   PubMed Web of Science ®Google Scholar
• Chambers S K, Wang Y, Gertz R E, et al. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 1995; 55: 1578–1585
   Google Scholar
• Hilbert D M, Kopf M, Mock B A, et al. lmerleukin-6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995; 182: 243–248
   PubMed Web of Science ®Google Scholar
• Spiekermann K, O'Brien S, Estey E. Relapse of acute myelogenous leukemia during low dose interleukin-2 therapy. Cancer 1995; 75: 1594–1597
   PubMed Web of Science ®Google Scholar
• Fitzpatrick D R, Manning L S, Musk A W, et al. Potential for cytokine treatment of malignant mesothelioma. Cancer Treat Rev 1995; 21: 273–288
   PubMed Web of Science ®Google Scholar
• Zeng F Y, Weiser W Y, Kratzin H, et al. The major binding protein of the interferon antagonist sarcolectin in human placenta is a macrophage migration inhibitory factor. Arch Biochem Biophys 1993; 303: 74–80
   PubMed Web of Science ®Google Scholar
• Sherblom A P, Sathyamoorthy N, Decker J M, et al. IL-2, a lectin with specificity for high mannose glycopeptides. J Immunol 1989; 143: 939–944
   PubMed Web of Science ®Google Scholar
• Gearing A JH, Newman W. Circulating adhesion molecules. Immunol Today 1993; 14: 506–512
   PubMedGoogle Scholar
• Lucas R, Magez S, De Leys R, et al. Mapping thelectin-like activity of tumor necrosis factor. Science 1994; 263: 814–317
   PubMed Web of Science ®Google Scholar
• Turunen J P, Majuri M L, Seppo A, et al. De novo expression of endothelial sialyl Lewisa and sialyl Lewisx during cardiac transplant rejection: Superior capacity of a tetravalent sialyl Lewisx oligosaccharide inhibiting L-selectin-dependent lymphocyte adhesion. J Exp Med 1995; 182: 1133–1142
   PubMed Web of Science ®Google Scholar
• Adler P, Wood S J, Lee Y C, et al. High affinity binding of the Entamoeba histolytica lectin to polyvalent N-acetylgalac-tosaminides. J Biol Chem 1995; 270: 5164–5171
   PubMed Web of Science ®Google Scholar
• Karlsson K A. Microbial recognition of target-cell glycoconjugates. Curr Opin Struct Biol 1995; 5: 622–635
   PubMed Web of Science ®Google Scholar
• Bertozzi C. Cracking the carbohydrate code for selectin recognition. Chem Biol 1995; 2: 703–708
   PubMed Web of Science ®Google Scholar
• Gabius H J, Kayser K, Gabius S. Protein-Zucker-Erkenming. Naturwissenschaften 1995; 82: 533–543
   PubMedGoogle Scholar
• Toyokuni T, Singhai A K. Synthetic carbohydrate vaccines based on tumor-associated antigens. Chem Soc Rev 1995; 24: 231–242
   Web of Science ®Google Scholar
• Chambers W H, Adamkiewicz T, Houchins J P. Type II integral membrane proteins with characteristics of C-type animal lectins expressed by natural killer (NK) cells. Glycobiology 1993; 3: 9–14
   PubMed Web of Science ®Google Scholar
• Bezouska K, Yuen C T, O'Brien J, et al. Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity. Nature 1994; 372: 150–157
   PubMed Web of Science ®Google Scholar
• Daniels B F, Nakamura M C, Rosen S D, et al. Ly49A, a receptor for H-2Dd, has a functional carbohydrate recognition domain. Immunity 1994; 1: 785–792
   PubMed Web of Science ®Google Scholar
• Kawakami K, Yamamoto K, Toyoshima S, et al. Dual function of macrophage galactose/N-acetylgalactosamine-specific lectins: Glycoprotein uptake and tumoricidal cellular recognition. Jpn J Cancer Res 1994; 85: 744–749
   PubMedGoogle Scholar
• Lanier L L, Chang C, Phillips J H. Human NKR-P1 A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994; 153: 2417–2428
   PubMed Web of Science ®Google Scholar
• Brennan J, Takei F, Wong S, et al. Carbohydrate recognition by a natural killer cell receptor, Ly-49C. J Biol Chem 1995; 270: 9691–9694
   PubMed Web of Science ®Google Scholar
• Chambers W H, Brisette-Storkus C S. Hanging in the balance: Natural killer cell recognition of target cells. Chem Bid 1995; 2: 429–435
   PubMed Web of Science ®Google Scholar
• Ryan J C, Niemi E C, Nakamura M C, et al. NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity. J Exp Med 1995; 181: 1911–1915
   PubMed Web of Science ®Google Scholar
• Yokoyama W M. Hybrid resistance and the Ly-49 family of natural killer cell receptors. J Exp Med 1995; 182: 273–277
   PubMed Web of Science ®Google Scholar
• Glycosciences: Status and Perspectives, H J Gabius, S Gabius. Chapman & Hall, London 1997
   Google Scholar
• Stent G. That was the molecular biology that was. Science 1968; 160: 390–395
   PubMed Web of Science ®Google Scholar
• Kawade Y. Four stages in the history of interferon research. J Interfer Res 1987; 7: 461–465
   PubMedGoogle Scholar
• Krown S E. Interferons in malignancy: Biological products or biological response modifiers. J Natl Cancer Inst 1988; 80: 306–309
   PubMed Web of Science ®Google Scholar